Olin Announces Third Quarter 2026 Results

Olin reported Q3 2026 adjusted EBITDA of $191.4 million, down from $222.4 million a year earlier, while net income attributable to Olin fell to $14.4 million, or $0.13 per diluted share, from $42.8 million, or $0.37. Sales rose to $1.748 billion from $1.713 billion, with stronger Epoxy and Winchester results offset by weaker Chlor Alkali Products and Vinyls. Olin expects Q4 adjusted EBITDA of $80 million to $100 million, citing seasonality, customer destocking, higher feedstock costs, subsidized Asian exports and planned maintenance. Shareholders approved the proposed all-stock merger with Huntsman and the U.S. HSR waiting period expired; Olin now expects closing in Q1 2027, subject to remaining conditions and approvals.

Analysis

OLN’s risk is shifting from cyclical earnings weakness to balance-sheet sensitivity: at 5.2x net debt/adjusted EBITDA, a further EBITDA shortfall can constrain strategic flexibility and make equity value unusually sensitive to modest operating changes. The Q4 guide implies a steep sequential earnings step-down; seasonal destocking and turnarounds may explain part of it, but higher feedstock costs and subsidized Asian exports could make the pressure persist beyond the quarter. The key test on the October 30 call is whether management characterizes the weakness as timing or signals sustained deterioration in ECU pricing, volumes, or cash generation.

There is an offset: restored VCM operations remove a prior operational drag, and Epoxy’s return to near breakeven suggests cost actions are helping. But those improvements have not yet translated into stronger consolidated cash generation; working-capital absorption and capital spending have left little room for balance-sheet repair. Winchester is a relative stabilizer, though raw-material inflation can erode its progress if pricing lags.

For Huntsman, shareholder approval and progress on conditions reduce execution uncertainty, but do not establish the value or timing of synergies. The merger is not a near-term earnings cure for OLN’s leverage, and pre-close planning should not be treated as realized savings. Competitive pressure from Asian chemical exports also limits confidence that combined scale alone restores pricing. The thesis improves if Q4 cash flow and 2027 EBITDA expectations stabilize; it breaks if further guidance cuts or weaker ECU economics push leverage higher.

Key Decisions for Investors

• Keep OLN underweight / avoid adding ahead of the October 30 call. Reassess only if management demonstrates that Q4 is a temporary trough and cash conversion improves; a further EBITDA reduction or weaker 2027 outlook would reinforce downside risk.
• Use a defined-risk OLN put spread as a tactical hedge only if option pricing is reasonable; the near-term catalyst is the earnings call, while the main risk to the hedge is a reassuring outlook plus VCM normalization. Do not set strikes without current share price and implied-volatility data.
• Treat HUN as a merger-condition and deal-terms watch, not a standalone merger-arbitrage recommendation: verify the exchange mechanics, remaining regulatory approvals, and any closing conditions before sizing exposure. A delay or remedy that changes expected economics would reverse the improved completion outlook.
• Monitor quarterly operating cash flow, net debt/adjusted EBITDA, and caustic/ECU pricing alongside Asian export pressure. Sustained cash generation and leverage stabilization would falsify the bearish balance-sheet thesis; another rise in leverage would strengthen it.